On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of down syndrome

Developmental Neuroscience

Volumn 33, Issue 5, 2011, Pages 414-427

  Costa, Alberto C S ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Developmental disability; Drug therapy; Intellectual disability; Memantine; N methyl D aspartate receptors; Trisomy 21; Ts65Dn mice

Indexed keywords

DIZOCILPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER;

AGGRESSION; ALZHEIMER DISEASE; AMNESIA; BRAIN DEVELOPMENT; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONVULSION; DEGENERATIVE DISEASE; DISEASE MODEL; DIZZINESS; DOWN SYNDROME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DYSKINESIA; HUMAN; HYPERTENSION; LEARNING DISORDER; MEDICAL RESEARCH; MENSTRUATION DISORDER; NAUSEA; NERVOUSNESS; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; TREMOR; VESICULAR RASH;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NERVE DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 83055172862     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000330861     Document Type: Review

References (93)

1. Lejeune J: Le mongolism: premier exemple d'aberration autosomique humaine. Ann Genet 1959; 1: 1-49.
2. Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, Devine O, Petrini J, Ramadhani TA, Hobbs CA, Kirby RS: National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 2006; 76: 747-756.
3. Bittles AH, Glasson EJ: Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol 2004; 46: 282-286.
4. Romano C, Tine A, Fazio G, Rizzo R, Colognola RM, Sorge G, Bergonzi P, Pavone L: Seizures in patients with trisomy 21. Am J Med Genet Suppl 1990; 7: 298-300.
5. Pueschel SM, Louis S, McKnight P: Seizure disorders in Down syndrome. Arch Neurol 1991; 48: 318-320.
6. Janicki MP, Dalton AJ: Prevalence of dementia and impact on intellectual disability services. Ment Retard 2000; 38: 276-288.
7. Webber A, Virji-Babul N, Edwards R, Lesperance M: Stiffness and postural stability in adults with Down syndrome. Exp Brain Res 2004; 155: 450-458.
8. Aruin AS, Almeida GL, Latash ML: Organization of a simple two-joint synergy in individuals with Down syndrome. Am J Ment Retard 1996; 101: 256-268.
9. Holland AJ, Hon J, Huppert FA, Stevens F: Incidence and course of dementia in people with Down's syndrome: findings from a population- based study. J Intellect Disabil Res 2000; 44: 138-146.
10. Haslam R: Neurological problems associated with Down syndrome; in Nadel LE, Rosenthal DE (eds): Down Syndrome: Living and Learning in the Community. New York, Wiley-Liss, 1995, pp 107-114.
11. Davisson M, Schmidt C, Akeson E: Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res 1990; 360: 263-280.
12. Li ZY, Yu T, Morishima M, Pao A, LaDuca J, Conroy J, Nowak N, Matsui SI, Shiraishi I, Yu YE: Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum Mol Genet 2007; 16: 1359-1366.
13. O'Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, Cooke S, Sesay A, Modino S, Vanes L, Hernandez D, Linehan JM, Sharpe PT, Brandner S, Bliss TVP, Henderson DJ, Nizetic D, Tybulewicz VLJ, Fisher EMC: An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005; 309: 2033-2037.
14. Olson LE, Richtsmeier JT, Leszl J, Reeves RH: A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004; 306: 687-690.
15. Sago H, Carlson EJ, Smith DJ, Kilbridge J, Rubin EM, Mobley WC, Epstein CJ, Huang TT: Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci USA 1998; 95: 6256-6261.
16. Patterson D, Costa AC: Down syndrome and genetics - a case of linked histories. Nat Rev Genet 2005; 6: 137-147.
17. Gardiner K, Costa AC: The proteins of human chromosome 21. Am J Med Genet C Semin Med Genet 2006; 142C:196-205.
18. Rachidi M, Lopes C: Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol 2008; 12: 168-182.
19. Davisson MT, Costa ACS: Mouse models of Down syndrome; in Popko B (ed): Advances in Neurochemisty. New York, Kluwer Academic/ Plenum Publishers, 1999, vol 9, pp 297-327.
20. Seregaza Z, Roubertoux PL, Jamon M, Soumireu- Mourat B: Mouse models of cognitive disorders in trisomy 21: a review. Behav Genet 2006; 36: 387-404.
21. Williams AD, Mjaatvedt CH, Moore CS: Characterization of the cardiac phenotype in neonatal Ts65Dn mice. Dev Dyn 2008; 237: 426-435.
22. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L: The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev 2003; 74: 75-93.
23. Edgin JO, Mason GM, Allman MJ, Capone GT, Deleon I, Maslen C, Reeves RH, Sherman SL, Nadel L: Development and validation of the Arizona Cognitive Test Battery for Down syndrome. J Neurodev Disord 2011; 2: 149-164.
24. Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH: Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 2000; 9: 195-202.
25. Green EL, Laboratory RBJM, et al: Biology of the Laboratory Mouse. New York, McGraw- Hill, 1966.
26. Sturgeon X, Gardiner KJ: Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome 2011; 22: 261-271.
27. Yu T, Li Z, Jia Z, Clapcote SJ, Liu C, Li S, Asrar S, Pao A, Chen R, Fan N, Carattini-Rivera S, Bechard AR, Spring S, Henkelman RM, Stoica G, Matsui S, Nowak NJ, Roder JC, Chen C, Bradley A, Yu YE: A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 2010; 19: 2780-2791.
28. Rueda N, Florez J, Martinez-Cue C: Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 2008; 433: 22-27.
29. Moran TH, Capone GT, Knipp S, Davisson MT, Reeves RH, Gearhart JD: The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol Behav 2002; 77: 403-409.
30. Lockrow J, Prakasam A, Huang P, Bimonte- Nelson H, Sambamurti K, Granholm AC: Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol 2009; 216: 278-289.
31. Hunter CL, Bimonte HA, Granholm ACE: Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav Brain Res 2003; 138: 121-131.
32. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, Garner CC: Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10: 411-413.
33. Clark S, Schwalbe J, Stasko MR, Yarowsky PJ, Costa ACS: Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol 2006; 200: 256-261.
34. Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, Grossi G, Fernandez M, Giuliani A, Calza L, Bartesaghi R: Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010; 30: 8769-8779.
35. Bianchi P, Ciani E, Contestabile A, Guidi S, Bartesaghi R: Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol 2009; 20: 106-118.
36. Costa ACS, Scott-McKean JJ, Stasko MR: Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33: 1624-1632.
37. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC: Restoration of norepinephrine-modulated contextual memory in a mouse model of down syndrome. Sci Transl Med 2009; 1: 7ra17.
38. Moon J, Chen M, Gandhy SU, Strawderman M, Levitsky DA, Maclean KN, Strupp BJ: Perinatal choline supplementation improves cognitive unctioning and emotion regulation in the Ts65Dn mouse model of down syndrome. Behav Neurosci 2010; 124: 346-361.
39. Rueda N, Llorens-Martin M, Florez J, Valdizan E, Banerjee P, Trejo JL, Martinez-Cue C: Memantine normalizes several phenotypic features in the Ts65Dn mouse model of down syndrome. J Alzheimers Dis 2010; 21: 277-290.
40. Incerti M, Toso L, Vink J, Roberson R, Nold C, Abebe D, Spong CY: Prevention of learning deficit in a down syndrome model. Obstet Gynecol 2011; 117: 354-361.
41. Vink J, Incerti M, Toso L, Roberson R, Abebe D, Spong CY: Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl- D -aspartic acid and gamma-aminobutyric acid receptors. Am J Obstet Gynecol 2009; 200: 1-4.
42. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC: Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 2010; 221: 610-622.
43. Noll C, Planque C, Ripoll C, Guedj F, Diez A, Ducros V, Belin N, Duchon A, Paul JL, Badel A, de Freminville B, Grattau Y, Blehaut H, Herault Y, Janel N, Delabar JM: DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase. PLoS One 2009; 4:e7540.
44. Eisch AJ, Cameron HA, Encinas JM, Meltzer LA, Ming GL, Overstreet-Wadiche LS: Adult neurogenesis, mental health, and mental illness: hope or hype? J Neurosci 2008; 28: 11785-11791.
45. Virji-Babul N, Eichmann A, Kisly D, Down J, Haslam RHA: Use of health care guidelines in patients with Down syndrome by family physicians across Canada. Paediatr Child Health 2007; 12: 179-183.
46. Myers BA, Pueschel SM: Major depression in a small group of adults with Down syndrome. Res Dev Disabil 1995; 16: 285-299.
47. Blanchard DC, Blanchard RJ, Lee EMC, Fukunaga KK: Movement arrest and hippocampus. Physiol Psychol 1977; 5: 331-335.
48. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC: Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 2004; 24: 8153-8160.
49. Costa ACS, Grybko MJ: Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci Lett 2005; 382: 317-322.
50. Fernandez F, Garner CC: Over-inhibition: a model for developmental intellectual disability. Trends Neurosci 2007; 30: 497-503.
51. Sonkusare SK, Kaul CL, Ramarao P: Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope. Pharmacol Res 2005; 51: 1-17.
52. Danysz W, Parsons CG: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18:S23-S32.
53. Wenk GL, Parsons CG, Danysz W: Potential role of N-methyl- D -aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 2006; 17: 411-424.
54. Villmann C, Becker CM: On the hypes and falls in neuroprotection: targeting the NMDA receptor. Neuroscientist 2007; 13: 594-615.
55. Gardiner K: Predicting pathway perturbations in Down syndrome. J Neural Transm Suppl 2003; 67: 21-37.
56. Lieberman DN, Mody I: Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 1994; 369: 235-239.
57. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zeng H, Caron MG, Tonegawa S: Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA 2003; 100: 8987-8992.
58. Phillips RG, Ledoux JE: Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Beh Neurosci 1992; 106: 274-285.
59. Sananbenesi F, Fischer A, Schrick C, Spiess J, Radulovic J: Phosphorylation of hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during contextual fear conditioning: interactions between Erk-1/2 and Elk-1. Mol Cell Neurosci 2002; 21: 463-476
60. Nadel L: Neural and cognitive development in Down syndrome; in Nadel L, Rosenthal D (eds): Down Syndrome: Living and Learning in the Community. New York, Wiley-Liss, 1995, pp 107-114.
61. Wishart JG: Cognitive abilities in children with Down syndrome: developmental instability and motivational deficits; in Epstein CJ, Hassold TJ, Lott IT, Nadel L, Patterson D (eds): Etiology and Pathogenesis of Down Syndrome. New York, Wiley-Liss, 1995, pp 57-92.
62. Yates CM, Simpson J, Gordon A, Maloney AFJ, Allison Y, Ritchie IM, Urquhart A: Catecholamines and cholinergic enzymes in presenile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 1983; 280: 119-126.
63. Godridge H, Reynolds GP, Czudek C, Calcutt NA, Benton M: Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry 1987; 50: 775-778.
64. Mann DMA, Jones D, Prinja D, Purkiss MS: The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Acta Neuropathol 1990; 80: 318-327.
65. Leverenz JB, Raskind MA: Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 1998; 150: 296-304.
66. Zigman W, Schupf N, Haveman M, Silverman W: The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference. J Intellect Disabil Res 1997; 41: 76-80.
67. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, Growdon J, Bruni A, Foncin JF, Salmon D, Frommelt P, Amaducci L, Sorbi S, Piacentini S, Stewart GD, Hobbs WJ, Conneally PM, Gusella JF: The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987; 235: 885-890.
68. Goate A, Chartierharlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericakvance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
69. Turner S, Alborz A: Academic attainments of children with Down's syndrome: a longitudinal study. Br J Educ Psychol 2003; 73: 563-583.
70. Pueschel SM, Hopmann MR: Speech and language abilities of children with Down syndrome: a parent's perspective; in Kaiser AP, Gray DB (eds): Enhancing Children's Communication: Research Foundations for Intervention Communication and Language Intervention Series. Baltimore, Brookes Publishing Company 1993, vol 2, pp 335-362.
71. Carr J: Six weeks to twenty-one years old: a longitudinal study of children with Down's syndrome and their families. Third Jack Tizard memorial lecture. J Child Psychol Psychiatry 1988; 29: 407-431.
72. Vicari S, Marotta L, Carlesimo GA: Verbal short-term memory in Down's syndrome: an articulatory loop deficit? J Intellect Disabil Res 2004; 48: 80-92.
73. Vicari S, Caselli MC, Gagliardi C, Tonucci F, Volterra V: Language acquisition in special populations: a comparison between Down and Williams syndromes. Neuropsychologia 2002; 40: 2461-2470.
74. Jarrold C, Baddeley AD, Hewes AK: Verbal short-term memory deficits in Down syndrome:a consequence of problems in rehearsal? J Child Psychol Psychiatry 2000; 41: 233-244.
75. Brock J, Jarrold C: Serial order reconstruction in Down syndrome: evidence for a selective deficit in verbal short-term memory. J Child Psychol Psychiatry 2005; 46: 304-316.
76. Abbeduto L, Pavetto M, Kesin E, Weissman MD, Karadottir S, O'Brien A, Cawthon S: The linguistic and cognitive profile of Down syndrome: evidence from a comparison with fragile X syndrome. Downs Syndr Res Pract 2001; 7: 9-15.
77. Silverman W: Down syndrome: cognitive phenotype. Ment Retard Dev Disabil Res Rev 2007; 13: 228-236.
78. Hodapp R, Zigler E: New issues in the developmental approach to mental retardation; in MacLean W (ed): Ellis' Handbook of Mental Deficiency, Psychological Theory and Research. Mahwah, Erlbaum, 1997, pp 115-136.
79. Parsons CG, Stoffler A, Danysz W: Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699-723.
80. McShane R, Sastre AA, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006; 19:CD003154.
81. Findling RL, McNamara NK, Stansbrey RJ, Maxhimer R, Periclou A, Mann A, Graham SM: A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention- deficit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol 2007; 17: 19-33.
82. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ: A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 2007; 191: 141-147.
83. Chez MG, Burton Q, Dowling T, Chang MN, Khanna P, Kramer C: Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007; 22: 574-579.
84. Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, Heller JH, Richardson S, McRae T: The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A 2009; 149A:1641-1654.
85. Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, Zhang R, McRae T: Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A 2011; 152A:3028-3035.
86. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B: Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011; 3: 64ra61.
87. Costa AC, Stasko MR, Schmidt C, Davisson MT: Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). Behav Brain Res 2010; 206: 52-62.
88. Knapp M, Comas-Herrera A, Astin J, Beecham J, Pendaries C: Intellectual disability, challenging behaviour and cost in care accommodation: what are the links? Health Soc Care Community 2005; 13: 297-306.
89. Stanwood GD, Levitt P: Drug exposure early in life: functional repercussions of changing neuropharmacology during sensitive periods of brain development. Curr Opin Pharmacol 2004; 4: 65-71.
90. Davis KL, Samuels SC: Dementia and delirium; in Enna SJ, Coyle JT (eds): Pharmacological Management of Neurological and Psychiatric Disorders. New York, McGraw- Hill, 1998, pp 267-316.
91. Chicoine B, McGuire D, Rubin SS: Specialty clinic perspective; in Janicki MP, Dalton AJ (eds): Dementia, Aging, and Intellectual Disabilities: A Handbook. Philadelphia, Taylor and Francis, 1999, pp 278-293.
92. Margallo-Lana ML, Ballard C, Morris C, Kay D, Tyrer S, Moore B: Cognitive decline in Down syndrome. Arch Neurol 2003; 60: 1024, author reply 1024.
93. Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A, Carlson EJ, Staufenbiel M, Nixon RA: App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci 2003;23:6788-6792